• Vaccine Name: N. caninum NcMAG1 Protein Vaccine
• Target Pathogen: Neospora caninum
• Target Disease: Neosporosis
• Vaccine Ontology ID: VO_0011564
• Type: Subunit vaccine
• Status: Research
• MAG1 gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001267
• Immunization Route: Intraperitoneal injection (i.p.)

Mouse Response

• Host Strain: C57Bl/6
• Vaccination Protocol: At the age of 8–9 weeks, mice were randomly distributed into 10 experimental groups of 10 mice each, and the serological status (Neospora-negative) was checked by enzyme-linked immunosorbent assay (ELISA). Mice in groups 1–5 were treated by i.p. injection; mice in group 1 received 100 μl of PBS each (i.p. infection control), group 2 received 100 μl saponin adjuvant (SAP) at 100 μg/ml, group 3 received 10 μg of recNcPDI in SAP, group 4 received 10 μg recNcROP2 in SAP, group 5 received 10 μg recNcMAG1 in SAP. Mice in groups 6–10 were treated by i.n. application through the nares, which was performed under mild isoflurane anaesthesia. Mice in group 6 received 100 μl of PBS/mouse (i.n. infection control), group 7 received 20 μl of cholera toxin adjuvant (CT) at 250 μg/ml, group 8 received 10 μg recNcPDI/mouse in CT, group 9 received 10 μg recROP2 in CT, group 10 received 10 μg recNcMAG1 in CT. These procedures were carried out on days 1, 15 and 30 (Debache et al., 2010).
• Challenge Protocol: On day 46 all animals were challenged by i.p. inoculation of 1×10^6 freshly purified N. caninum tachyzoites. On day 74, the experiment was terminated and mice were euthanized by CO2 asphyxiation. Those animals exhibiting clinical signs of neosporosis (ruffled coat, apathy, hind limb paralysis) prior to day 74 were euthanized at the onset of these signs (Debache et al., 2010).
• Efficacy: recNcMAG1 provided protection in 7 and 5 out of 10 mice, respectively, that did not develop any clinical signs (Debache et al., 2010).